8-K: Coeptis Therapeutics Announces Non-Reliance on Past Financial Statements Due to Accounting Errors

Coeptis Therapeutics has determined that previously issued financial statements for multiple periods should no longer be relied upon due to accounting errors related to note agreements.

Summary

• Coeptis Therapeutics has identified accounting errors related to how note agreements were recorded.
• The company's audit committee determined that the unaudited financial statements for the period ended September 30, 2023, the audited financial statements for the year ended December 31, 2023, and the unaudited financial statements for the period ended March 31, 2024, should no longer be relied upon.
• Additionally, financial statements included in registration statements filed on February 14, 2023, and November 15, 2023, should also not be relied upon.
• The errors involve recording notes receivable as subscription receivables.
• As of August 12, 2024, the balance of the subscription receivables has been satisfied.
• The company plans to restate the affected financial statements as soon as practicable.

Sentiment

Score: 3

Explanation: The document reveals significant accounting errors and the need for restatements, which is a negative development. While the company is taking steps to rectify the situation, the uncertainty and potential risks associated with the restatement process and potential litigation weigh heavily on the sentiment.

Positives

• The company has identified and acknowledged the accounting errors.
• The subscription receivables have been satisfied as of August 12, 2024.
• The company is taking steps to restate the financial statements as soon as practicable.
• The company hired a full-time Chief Financial Officer in 2023 to improve financial controls.

Negatives

• The company's previously issued financial statements for multiple periods are unreliable.
• There were weaknesses in the company's disclosure controls and procedures during 2022 and 2023.
• The restatement process may be costly and divert resources.
• The company may face litigation or regulatory action due to the restatements.
• The restatements could negatively impact the company's reputation and stock value.

Risks

• The company may face challenges in completing the restatements of the financial statements.
• There is a risk of material weaknesses in internal control over financial reporting.
• The company may experience reputational damage due to the restatements.
• The restatements could negatively impact the value of the company's common stock.
• The restatement process may take longer than anticipated.

Future Outlook

The company expects to file the restated financial statements as soon as practicable, but there are risks and uncertainties associated with this process.

Management Comments

• Management concluded that its accounting for note agreements recorded as notes receivable did not give full effect to the transactions.
• The company believes the hiring of a full-time Chief Financial Officer has and will continue to provide for improved processes related to controls and procedures.

Industry Context

Restatements of financial statements are not uncommon, but they can raise concerns about a company's internal controls and financial reporting practices. This event may lead investors to scrutinize Coeptis's financials more closely.

Comparison to Industry Standards

• Many companies, especially smaller ones, face challenges in maintaining robust internal controls, leading to restatements.
• Companies like Cassava Sciences and Ocugen have also faced scrutiny over their financial reporting, highlighting the importance of accurate accounting practices.
• The speed and transparency with which Coeptis addresses these issues will be critical in restoring investor confidence, similar to how other companies have navigated such situations.

Legal Proceedings

• There is a risk of litigation or regulatory action arising from the restatements of the financial statements.

Stakeholder Impact

• Shareholders may experience a negative impact on the value of their investment due to the restatements.
• Employees may be affected by the diversion of resources to address the restatements.
• Creditors may be concerned about the company's financial stability.

Next Steps

• The company will restate the affected financial statements.
• The company will address any material weaknesses in internal control over financial reporting.
• The company will work with its independent auditor to complete the restatements.

Key Dates

Keywords

financial restatement, accounting errors, non-reliance, financial statements, internal controls, subscription receivables, note agreements, audit committee